Pfizer persuades Read to stay another year; House GOP to take another crack at "right to try"; Lundbeck plans to acquire Prexton Therapeutics.
How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
FDA moves to limit nicotine in cigarettes; Alexion reports positive test for rare blood disorder treatment; Oregon governor signs drug pricing transparency bill.
MM&M spoke with Gazzaley about what's next for Akili, how he defines "digital medicine," and where the field is currently positioned on the hype cycle.
Why the U.S. spends more on healthcare with worse results; Alnylam goes it alone on rare disease therapy; MorphoSys hopes for accelerated approval on MOR208.
As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.
UnitedHealth names Witty as Optum CEO; Gilead R&D chief to exit; Novartis ups chief digital officer to executive committee.
Direct-to-consumer drug marketing spend dropped most heavily in the magazine and digital categories.
Health's popularity at SXSW continues to build. Here's our opening weekend wrap-up.
Regeneron, Sanofi cut cost of Praluent for wider coverage; GSK to maintain Advair exclusivity for 2018; 'Right to try' bill introduced in House.